News

Novo Nordisk and US biotech company team up to create obesity pills
Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...
Novo Nordisk CEO's surprise exit after setbacks in weight-loss market: Reaction
Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...
Novo Nordisk CEO to step down as obesity drug competition intensifies
Novo Nordisk CEO Lars Jørgensen to step down amid increasing pressure from obesity drug competition and recent share price ...
Here’s Why Polen Focus Growth Strategy Exited Novo Nordisk A/S (NVO)
Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” first quarter 20245 investor ...
Novo Nordisk posts strong Q1 as weight-loss revolution claims another victim: WeightWatchers
The company’s blockbuster drugs helped it beat Wall Street’s expectations—while WeightWatchers declares bankruptcy. One day ...
Novo Nordisk: Nothing Has Changed, Except That It's Cheaper Now
Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases.
Novo Nordisk, U.S. biotech company team up to create obesity pills
Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...
Novo Nordisk CEO's Surprise Exit After Setbacks in Weight-Loss Market
"The Novo Nordisk Foundation is increasing its influence and has appointed its chairman, Lars Rebien Sørensen, as an observer ...